MDWD - MediWound adds 13% after favorable data for ulcer candidate

• Israeli biopharma MediWound ( NASDAQ: MDWD ) climbed ~13% in the pre-market Thursday after the company announced positive data from a Phase 2 trial designed to evaluate its wound candidate EscharEx as a therapy for the debridement of lower leg ulcers.
• The U.S.-based open-label, single-arm trial involved 12 patients with venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs) who received up to eight daily applications of EscharEx, a treatment designed for the outpatient setting.
• After about eight applications of EscharEx, 70% of patients achieved complete debridement during the treatment course. Complete debridement was reached in about 3.9 applications on average. There was an average of 35% reduction of wound size after a two-week follow up period.
• “The data from our pharmacology study corroborates the results of our previous Phase 2 studies, and clearly supports EscharEx as a potential rapid and effective, non-surgical debriding agent,” MediWound ( MDWD ) Chief Executive Ofer Gonen said.

For further details see: